How to contribute?

We are working on a solution to provide you with a form-based interface for the submission of new content.
In the meantime, the submission of content is done as follows:

As a contributor, you just have to grep the LHA Excel Template below and submit it to the LHA team. Whenever you decide to hand in an entity, you can generate respective LHA IDs below. For details on how to fill the Excel, see Guided Tour: Ontology-Based Specification and Import of Content Into the Leipzig Health Atlas.

For each entry, you have to decide if attachments, e.g., data sets with patient data, binaries of programmatic models or images, should be accessible by everyone, or if the access should be restricted to specific user groups (e.g., your research group or institute), determined by a whitelist.

After your submission, expect the following scenarios to occur:

  • People will download and try your provided public attachments.
  • Some of them will have a greater interest and will try to contact you to get more information or to pose questions.
  • A fraction of the interested people will cite you, or even want to start a cooperation.

LHA ID Generator

Specify the number of LHA-IDs to be generated.

Entity List

LHA-ID Title Content type
7Q6RC6MK10-0 BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. Publication
7R9DC2M38K-3 Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Publication
7QFXD9A4DT-6 Body typing of children and adolescents using 3D-body scanning Publication
7Q6RC6792V-4 Brain Arousal Regulation in Carriers of Bipolar Disorder Risk Alleles. Publication
7R9DC241GV-8 Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Publication
7R9DC0HP3R-0 Chemotherapy for intracranial ependymoma in adults. Publication
7RWQGAVHXK-3 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Publication
7Q0CR2P4MK-3 CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Publication
7Q0CEYUHXW-1 Claus Model
7Q0CG2J3X0-7 Clinical data from patients with cerebral tumors of WHO grade II and III Clinical Dataset
7Q0CG2J3VH-7 Clinical data from patients with glioblastoma Clinical Dataset
7Q0CR2P425-0 Clinical data from patients with high-risk Non-Hodgkin's-Lymphoma aged
18-60 years
Clinical Dataset
7Q0CTG2N72-3 Clinical data from patients with untreated aggressive Non-Hodgkin's-Lymphoma aged 61-80 years without relevant concomittant diseases Clinical Dataset
7Q0CR2P50P-8 Clinical data from patients with untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma aged 18-60 years Clinical Dataset
7Q0CR2P4YR-8 Clinical data from patients with untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma aged 18-60 years (Follow-up) Clinical Dataset
7RX4165T77-8 Clinical trials for patients with B-cell lymphoma of the German High-grade Non-Hodgkin's Lymphoma study group (DSHNHL)/ German Lymphoma Alliance (GLA) Project
7Q6RC70N8M-9 Common genomic variation in the FER gene: useful to stratify patients with sepsis due to pneumonia? Publication
7Q6RC6668T-6 Components of a Mediterranean diet and their impact on cognitive functions in aging Publication
7Q0CHUQAN6-1 Compression of Dementia Morbidity by Higher Education Publication
7Q6RC5JUC6-8 Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia. Publication